| Pulido, Enrique Grande |
| Active, not recruiting | 1/2 | 429 | Europe, US, RoW | Acasunlimab, GEN1046, DuoBody®-PD-L1x4-1BB, Acasunlimab in combination with docetaxel (in a single expansion cohort), Acasunlimab in combination with pembrolizumab (in a separate expansion cohort), Acasunlimab in combination with pembrolizumab and standard chemotherapy (in separate expansion cohorts) | Genmab, BioNTech SE | Solid Tumors, Non-small Cell Lung Cancer, Urothelial Carcinoma, Endometrial Carcinoma, Triple Negative Breast Cancer, Squamous Cell Carcinoma of the Head and Neck, Cervical Cancer | 01/25 | 10/25 | | |
| Sponsor, Principal Investigator Selected by |
| Recruiting | 3 | 526 | Europe | Tinzaparin, Innohep | Galician Research Group on Digestive Tumors, LEO Pharma | Colorectal Cancer Metastatic, Thromboembolism | 12/24 | 03/25 | | |
| Active, not recruiting | 2 | 48 | Europe | encorafenib, Braftovi, binimetinib, Mektovi, Whole brain radiation therapy, Radiosurgery/stereotactic radiosurgery | Grupo Español Multidisciplinar de Melanoma, Pierre Fabre Medicament, MFAR | Metastatic Melanoma, Brain Metastases | 10/22 | 10/23 | | |
GETNE-T1913, NCT03980925 / 2019-001546-18: Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin. |
|
|
| Active, not recruiting | 2 | 38 | Europe | Nivolumab, Carboplatin, Etoposide | Grupo Espanol de Tumores Neuroendocrinos | Neuroendocrine Tumors, Neuroendocrine Neoplasm, Gastroenteropancreatic Neuroendocrine Tumor | 02/23 | 12/23 | | |
DUTHY, NCT03753919: Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The Trial |
|
|
| Active, not recruiting | 2 | 79 | Europe | Durvalumab, MEDI4736, Tremelimumab | Grupo Espanol de Tumores Neuroendocrinos, MFAR | Metastatic Thyroid Papillary Carcinoma, Metastatic Thyroid Follicular Carcinoma, Metastatic Thyroid Cancer | 07/24 | 12/24 | | |
CABATEN, NCT04400474: Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The Study |
|
|
| Active, not recruiting | 2 | 93 | Europe | Cabozantinib 40 mg, Atezolizumab 1200 mg | Grupo Espanol de Tumores Neuroendocrinos, Ipsen, Roche Pharma AG | Neuroendocrine Tumor, Anaplastic Thyroid Cancer, Adenocarcinoma, Pheochromocytoma, Paraganglioma | 12/23 | 03/24 | | |
LIVERPEARL, NCT04595266: Chemoembolization (Lifepearls-Irinotecan) in Patients With Colorectal Cancer and Metastatic Disease |
|
|
| Recruiting | 2 | 48 | Europe | FOLFOX regimen, Leucovorin/Fluorouracil/Oxaliplatin, Anti-EGFR or Bevacizumab, monoclonal antibody anti EGFR (RASwt) or Bevacizumab (RASmut), LIVERPEARLS-Irinotecan, Chemoembolization of Irinotecan in hydrogel microspheres | Grupo Espanol Multidisciplinario del Cancer Digestivo | Colorectal Cancer Metastatic, Liver Metastasis Colon Cancer | 01/24 | 01/25 | | |
SITISVEAL, NCT05542342: Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases. |
|
|
| Active, not recruiting | 2 | 16 | Europe | Tislelizumab, Sitravatinib Malate | Grupo Español Multidisciplinar de Melanoma, Mirati Therapeutics Inc., BeiGene | Uveal Melanoma | 12/23 | 05/24 | | |
PEMBROLA, NCT05201612: Pembrolizumab and Olaparib in Homologous-recombination Deficient (HRD) Advanced Colorectal Cancer (CRC). |
|
|
| Recruiting | 2 | 40 | Europe | Olaparib, Lynparza, Pembrolizumab, Keytruda | Grupo Espanol Multidisciplinario del Cancer Digestivo, Merk Sharp & Dohme España S.A. | Metastatic Colorectal Cancer | 09/24 | 03/25 | | |
| Recruiting | 2 | 66 | Europe | Nivolumab, Opdivo, Ipilimumab, Yervoy | Spanish Oncology Genito-Urinary Group, Bristol-Myers Squibb | Urothelial Cancer | 03/25 | 12/25 | | |
| Recruiting | 2 | 41 | Europe | Cabozantinib | Grupo Espanol de Tumores Neuroendocrinos, Ipsen, MFAR | Differentiated Thyroid Cancer | 06/25 | 06/25 | | |
| Recruiting | 2 | 45 | Europe | Atezolizumab plus Tiraglolumab | Grupo Espanol Multidisciplinario del Cancer Digestivo, Hoffmann-La Roche | Squamous Cell Carcinoma of the Anal Canal | 06/27 | 06/28 | | |
| Active, not recruiting | 1/2 | 20 | Europe | Atezolizumab 1200 mg in 20 ML Injection, Tecentriq, ADC Vaccine, Autologous Dendritic cell (ADC) vaccine, Dendritic cell (DC) vaccine, Carboplatin, Carboplatino (Teva/Accord/Pharmacia) | Instituto Oncológico Dr Rosell, Roche Pharma AG, Fundacion Clinic per a la Recerca Biomédica | Extensive-stage Small Cell Lung Cancer | 08/24 | 10/24 | | |
| Recruiting | 1/2 | 18 | Europe | Azeliragon 5 mg, Azeliragon 10 mg, Azeliragon 20 mg | Cantex Pharmaceuticals | Glioblastoma | 12/24 | 12/25 | | |
GEINOCANN, NCT03529448: TN-TC11G (THC+CBD) Combination With Temozolomide and Radiotherapy in Patients With Newly-diagnosed Glioblastoma |
|
|
| Recruiting | 1/2 | 30 | Europe | TN-TC11G, Temozolomide Oral Product, Temozolomide, Radiotherapy, STUPP | Grupo Español de Investigación en Neurooncología, Medical Cannabis Bike Tour, Voices Against Brain Cancer, Tilray | Glioblastoma | 03/25 | 12/25 | | |
CEB-01-RLS01-CT, NCT04619056: First-in-man Clinical Trial of CEB-01 PLGA Membrane in Recurrent or Locally Advanced Retroperitoneal Soft Tissue Sarcoma |
|
|
| Active, not recruiting | 1 | 21 | Europe | CEB-01 membrane loaded with SN-38 | CEBIOTEX | Locally Advanced Soft Tissue Sarcoma, Recurrent Soft Tissue Sarcoma | 05/25 | 05/25 | | |
| Recruiting | 1 | 32 | Europe | Repotrectinib, TPX-0005, Osimertinib, Tagrisso | Instituto Oncológico Dr Rosell, Turning Point Therapeutics, Inc. | Nsclc | 04/26 | 06/26 | | |
| Recruiting | N/A | 400 | Europe | | Grupo Espanol de Tumores Neuroendocrinos | Gastroenteropancreatic Neuroendocrine Tumor | 07/23 | 12/23 | | |
| Recruiting | N/A | 20 | Europe | | Grupo Espanol de Tumores Neuroendocrinos | Thyroid Cancer | 12/23 | 12/23 | | |
TESEO, NCT03855592: Registry of Thrombosis & NEoplasia of "Sociedad Española de Oncología Médica" |
|
|
| Recruiting | N/A | 700 | Europe | | Fundación Sociedad Española de Oncologia Médica | Thromboembolism, Cancer | 07/24 | 07/24 | | |
REVEAL, NCT05674422: GEMCAD- STUDY - Circulating Tumor DNA as a Predictor of Relapse in Patients With Locally Advanced Rectal Cancer. |
|
|
| Recruiting | N/A | 120 | Europe | total neoadjuvant therapy | Grupo Espanol Multidisciplinario del Cancer Digestivo | Patients With Locally Advanced Rectal Cancer | 07/24 | 07/26 | | |
GEM-1801, NCT03605771: Descriptive Observational Study on the Characteristics of Advanced and Metastatic Melanoma in Spain |
|
|
| Recruiting | N/A | 400 | Europe | Daily Clinical Practice | Grupo Español Multidisciplinar de Melanoma | Melanoma Stage Iv, Melanoma Stage Iii, Advanced Cancer | 12/24 | 12/24 | | |
